TABLE 1.
Overview of the data included in the study
| Collected data | Studies | |||||
| Loci of interest | Total isolates | Isolation time frame years | Countries represented | Screened | Included | |
| Rifampicin (R) | rpoB | 13 424 | 1999–2014 | 37 | 459 | 95 |
| Isoniazid (H) | katG | 11 847 | 1992–2014 | 42 | 650 | 127 |
| inhA-mabA | 9407 | |||||
| furA | 361 | |||||
| mshA | 288 | |||||
| Ethionamide and prothionamide (ETO/PTO) | inhA-mabA | 346 | ||||
| ethA | 181 | |||||
| mshA | 117 | |||||
| Ofloxacin (OFX) | gyrA | 5911 | 1991–2013 | 36 | 243 | 75 |
| gyrB | 3078 | |||||
| Moxifloxacin (MFX) | gyrA | 1019 | ||||
| gyrB | 735 | |||||
| Levofloxacin (LFX) | gyrA | 449 | ||||
| gyrB | 218 | |||||
| Pyrazinamide (Z) | pncA | 4949 | 1990–2014 | 36 | 378 | 81 |
| Streptomycin (S) | rpsL | 3263 | 1985–2013 | 43 | 423 | 104 |
| tap | 0 | |||||
| rrs | 2598 | |||||
| whiB7 | 0 | |||||
| gidB | 812 | |||||
| Amikacin (AM) | rrs | 2105 | ||||
| Capreomycin (CM) | rrs | 2533 | ||||
| tlyA | 1854 | |||||
| Kanamycin (KM) | rrs | 1727 | ||||
| eis | 2029 | |||||
| whiB7 | 56 | |||||
Data are presented as n. Inclusion and exclusion criteria for individual studies are reported in online supplementary material 2.